Clinical trial NCT02432950: Pancreatic Nutritional Program for Weight Loss in Overweight/Obese Patients With Stage I-III Breast Cancer
Official title: PANCREATIC NUTRITIONAL PROGRAM (PNP): A Novel Weight Reduction Program in Overweight/Obese Breast Cancer Survivors
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Obesity
Stage IA Breast Cancer
Stage IB Breast Cancer
Stage IIA Breast Cancer
Stage IIB Breast Cancer
Stage IIIA Breast Cancer
Stage IIIB Breast Cancer
Stage IIIC Breast Cancer
Lead sponsor: City of Hope Medical Center
Sponsor class: OTHER
Collaborators: name: National Cancer Institute (NCI)
First posted: 2015-05-04
Enrollment: 21
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: This pilot clinical trial studies a pancreatic nutritional program for helping patients with stage I-III breast cancer who are overweight or obese lose weight. When patients have a high level of sugar in their blood, due to eating sugary foods and/or a sedentary lifestyle, the pancreas needs to work harder to digest the sugar. This can cause weight gain, obesity, and other illnesses. Breast cancer patients who are overweight and obese are more likely to have their breast cancer return. The pancreatic nutritional program is a diet and lifestyle intervention that helps protect the pancreas by keeping blood sugar levels low, and may help patients achieve sustained weight loss, improved health, better quality of life, and possibly a better outcome to their treatment.

Detailed description: PRIMARY OBJECTIVES:

I. To estimate the change in body weight at 6 months post-intervention relative to baseline.

SECONDARY OBJECTIVES:

I. To examine changes in: body composition; body chemistry; physical fitness; inflammatory markers; deoxyribonucleic acid (DNA) repair capacity; and quality of life per the Functional Assessment of Cancer Therapy - Breast (FACT-B)+4, version 4 questionnaire at 6 months post-intervention relative to baseline.

II. To describe adverse events possibly related to wearing the glucometer sensor or following the pancreatic nutritional program (PNP) diet.

III. To document compliance with the various components of the PNP (wearing the glucometer sensor; recording body weight; completing journal entries; completing meal cards; attending weekly counseling sessions with diet instructor).

OUTLINE:

Patients participate in the PNP intervention, which begins with a baseline meeting with a diet and lifestyle instructor to discuss baseline testing results, begin an educational plan, determine an individualized eating plan, and print out food choices. Patients also undergo automated glucometry every 15 minutes, review their individual food choices and blood glucose levels 90 minutes after eating, keep a daily nutrition and lifestyle journal log, fill out a daily meal discovery card log, and attend weekly meetings with a diet and lifestyle instructor for 12 weeks.

After completion of study, patients are followed up within 1 week and then at 6 months.

Eligibility criteria: Inclusion Criteria:

* Patients with early-stage breast cancer (stage I-III)
* Patients who have or have not undergone chemotherapy are both eligible; if the patient has undergone chemotherapy she must have completed adjuvant chemotherapy for \>= 3 months and =\< 5 years prior to study enrollment
* Postmenopausal women defined by either: natural menopause with at least one year since last menses, or chemotherapy-induced menopause with at least one year since last menses and follicle-stimulating hormone (FSH) and estradiol levels within the postmenopausal range
* Body mass index (BMI) of 25-33 kg/m\^2
* Patients must be willing to adhere to the PNP intervention and the entire 6-month study
* All patients must have the ability and the willingness to sign a written informed consent

Exclusion Criteria:

* Patients who are diabetic
* Patients whose BMI falls outside the eligible range (\< 25 kg/m\^2 or \> 33 kg/m\^2)
* Patients with stage IV breast cancer
* Patients with Rheumatoid Arthritis and other inflammatory diseases that would impact correlative studies

Primary outcomes:
measure: Change in body weight
timeFrame: Baseline to 6 months
Secondary outcomes:
measure: Change in body chemistry (lipid panel; comprehensive metabolic panel; complete blood count; fasting blood glucose; insulin resistance)
timeFrame: Baseline to up to 6 months
measure: Change in body composition (BMI)
timeFrame: Baseline to up to 6 months
measure: Change in physical fitness (measured using a handgrip dynamometer)
timeFrame: Baseline to 6 months
measure: Change in quality of life score (FACT-B+4)
timeFrame: Baseline to 6 months
measure: Change in serum inflammatory markers (C-reactive protein; cytokines)
timeFrame: Baseline to 6 months
measure: Compliance metrics (days glucometer sensor not utilized; days body weight not recorded; days journal entries not made; days meal cards not created; weekly counseling sessions missed)
timeFrame: 12 weeks
measure: DNA repair capacity (comet assay's mean olive tail moment; number of gamma-H2A histone family, member X foci)
timeFrame: Baseline to 6 months
measure: Incidence of adverse events reported as possibly or definitely related to wearing the glucometer sensor following the PNP diet
timeFrame: Up to 6 months
Other outcomes:
Locations:
city: Duarte
country: United States
facility: City of Hope Medical Center
state: California
Study officials:
affiliation: City of Hope Medical Center
name: Joanne Mortimer
role: PRINCIPAL_INVESTIGATOR
References: